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Abbreviations 34 
  
ATS American Thoracic Society 
CDC Centers for Disease Control and Prevention 
CIC Chronic Idiopathic Cough 
CINAHL Cumulative Index of Nursing and Allied Health Literature 
CQLQ Cough Quality of Life Questionnaire 
CTD Connective Tissue Disease 
CXR Chest Radiograph 
EB Eosinophilic Bronchitis 
EMBASE Excerpta Medica dataBASE 
ERS European Respiratory Society 
GERD Gastro-Esophageal Reflux Disease 
GI Gastro-Intestinal 
ILD Interstitial Lung Disease  
IPF Idiopathic Pulmonary Fibrosis 
MCID Minimal Clinically Important Difference 
LCQ Leicester Cough Questionnaire 
PICO Population, Intervention, Comparison, Outcome 
PPI Proton Pump Inhibitor 
PSALTI Physiotherapy and Speech And Language Therapy Intervention 
RCT Randomized Control Trial 
SGRQ St George’s Respiratory Questionnaire 
SPT Speech Pathology Therapy 
SSc Systemic Sclerosis 
TLCO Transfer Factor of the Lung for Carbon Monoxide  
UACS Upper Airway Cough Syndrome 
VAS Visual Analogue Score  
VC Vital Capacity 
 35 
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ABSTRACT 37 
BACKGROUND: Chronic cough in interstitial lung disease (ILD) causes significant 38 
impairment in quality of life. Effective treatment approaches are needed for cough associated 39 
with ILD.  40 
METHODS: This systematic review asked: Is there evidence of clinically relevant treatment 41 
effects for therapies for cough in ILD? Studies of adults aged > 18 years with a chronic cough 42 
> 8 weeks duration were included and assessed for relevance and quality. Based on the 43 
systematic review, guideline suggestions were developed and voted on by using CHEST 44 
guideline methodology. 45 
RESULTS: Eight Randomized Controlled Trials (RCT) and 2 case series (>10 patients) were 46 
included that reported data on patients with Idiopathic Pulmonary fibrosis (IPF), Sarcoidosis 47 
and Scleroderma-related ILD who received a variety of interventions. Study quality was high 48 
in all 8 RCTs. Inhaled corticosteroids were not supported for cough associated with 49 
Sarcoidosis. Cyclophosphamide and Mycophenolate were not supported for solely treating 50 
cough associated with scleroderma associated ILD. A recommendation for thalidomide to 51 
treat cough associated with IPF did not pass the panel vote. In view of the paucity of 52 
antitussive treatment options for refractory cough in ILD, the guideline panel suggested that 53 
the CHEST unexplained cough guideline be followed, by considering options such as the 54 
neuromodulator gabapentin and speech pathology management. Opiates were also suggested 55 
for patients with cough refractory to alternative therapies.  56 
CONCLUSIONS: The evidence supporting the management of chronic cough in ILD is 57 
limited. This guideline presents suggestions for managing and treating cough on the best 58 
available evidence but future research is clearly needed.  59 
KEY WORDS: chronic cough, interstitial lung disease, sarcoidosis, scleroderma, treatment, 60 
refractory, unexplained.  61 
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SUMMARY OF RECOMMENDATIONS AND SUGGESTIONS 62 
 63 
1.  For patients with ILD who present with a troublesome cough, we suggest that 64 
patients be assessed for progression of their underlying ILD, or complications from 65 
immunosuppressive treatment (e.g. drug side effect, pulmonary infection) and also be 66 
considered for further investigation / treatment trials for their cough according to 67 
guidelines for acute, subacute and chronic cough. (Ungraded Consensus- Based Statement) 68 
 69 
2. For patients with IPF, chronic cough and a negative workup for acid 70 
gastroesophageal reflux, we suggest that proton pump inhibitor therapy should not be 71 
prescribed.  (Ungraded Consensus- Based Statement)  72 
 73 
3.  For patients with pulmonary sarcoidosis, we suggest that inhaled corticosteroids 74 
should not be routinely prescribed to treat the chronic cough.  (Grade 2C).  75 
 76 
4. For patients with ILD and refractory chronic cough, we suggest trials of therapies 77 
recommended for patients with unexplained chronic cough according to the CHEST 78 
guidelines, with treatments such as gabapentin and multimodality speech pathology 79 
therapy, or entering into clinical trials if available. (Ungraded Consensus- Based 80 
Statement) 81 
 82 
5. For patients with chronic cough due to ILD, when alternative treatments have failed 83 
and the cough is adversely affecting their quality of life, we suggest that opiates be 84 
recommended for symptom control in a palliative care setting with reassessment of the 85 
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benefits and risks at 1 week and then monthly before continuing.  (Ungraded Consensus- 86 
Based Statement) 87 
  88 
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INTRODUCTION 89 
Interstitial lung disease (ILD) comprises a wide range of acute and chronic pulmonary 90 
disorders that affect both the airways and lung parenchyma with variable amounts of 91 
inflammation and fibrosis.   Cough is a common symptom associated with ILD, and may be 92 
the presenting symptom in some patients.  Cough in idiopathic pulmonary fibrosis (IPF) has 93 
been the best studied of all ILDs and a chronic cough is present in up to 80% of patients with 94 
IPF, although the proportion of patients with a troublesome cough is likely to be less than 95 
this1.  Cough in IPF has been assessed with validated tools, such as 24-hour cough monitoring 96 
and health-related Quality of Life questionnaires2. The health-related quality of life 97 
impairment in cough associated with IPF is significant and comparable with unexplained 98 
chronic cough 2,3. 99 
 100 
The presence of cough in IPF also has prognostic significance.  A recent study of 242 patients 101 
with IPF found that cough predicted disease progression, independent of disease severity4. 102 
Cough was more prevalent in patients with more advanced pulmonary fibrosis.  An important 103 
challenge when assessing cough in patients with ILD is to establish whether the cough is a 104 
consequence of the underlying inflammation or fibrosis, or due to the presence of a co-105 
morbidity.   In IPF, while the mechanism of cough may be mechanical distortion associated 106 
with lung parenchymal fibrosis5, heightened cough reflex sensitivity, gastro-esophageal reflux 107 
and airway inflammation have all been reported in patients with IPF and may therefore also 108 
be potentially important mechanisms6-8. 109 
 110 
Cough is also a common symptom in patients with pulmonary sarcoidosis.  A recent study by 111 
Sinha et al reported that 50% of patients had a chronic cough and this was associated with 112 
poor health-related quality of life9. Furthermore, there was a significant association between 113 
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the frequency of cough measured objectively with 24-hour cough monitoring and health-114 
related quality of life.  In the study by Sinha et al, cough reflex sensitivity assessed with 115 
capsaicin was the only independent predictor of the frequency of coughing. Lung function, 116 
disease activity or severity were not predictors of cough frequency. In scleroderma-related 117 
ILD, cough is also a prevalent symptom, and is associated with more severe interstitial lung 118 
disease10,11.   119 
 120 
The present systematic review addresses the problem of chronic cough associated with 121 
interstitial lung diseases, including sarcoidosis and scleroderma, in the areas of management 122 
and future directions. 123 
 124 
METHODS 125 
The methodology of the CHEST Guideline Oversight Committee was used to select the 126 
Expert Cough Panel chair and the international panel of experts to perform the systematic 127 
review, synthesis of the evidence, and development of the recommendations and 128 
suggestions12.  129 
 130 
Systematic Review Question 131 
The key clinical question for this systematic review, developed by the writing group, was: “Is 132 
there evidence of clinically relevant treatment effects for therapies for cough in ILD”. The 133 
literature search was generated following the creation of a PICO (population, intervention, 134 
comparison, outcome) element table (Table 1).  135 
 136 
 137 
 138 
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Literature search 139 
The search methods used for this systematic review conformed to those outlined in 140 
“Methodologies for the development of CHEST guidelines and expert panel reports”12. 141 
PubMed and the Cochrane Database of Systematic Reviews were searched for systematic 142 
reviews, and Scopus (includes EMBASE), PubMed, CINAHL (Cumulative Index of Nursing 143 
and Allied Health Literature) and the Cochrane Central Register of Controlled Trials were 144 
searched for other papers.  All databases were searched from the earliest available date until 145 
February 2016.  The search terms used are included in e-Appendix 1.   146 
 147 
Eligibility criteria were reached by consensus between all of the authors (table 1).  Given the 148 
relative paucity of data in this field, we included all study types including case series of more 149 
than 10 patients.  The titles and abstracts were reviewed independently by two of the authors 150 
(SB and JK) to identify potentially useful publications, based on the inclusion and exclusion 151 
criteria. Where differences occurred, consensus was achieved between the two reviewers.  152 
While a third independent reviewer was available if consensus could not be reached, lack of 153 
consensus did not occur. The full text of those abstracts selected as potentially relevant were 154 
then reviewed independently (again by SB and JK) against the eligibility criteria. The 155 
inclusion of a standardized cough outcome measure was acceptable as a primary or secondary 156 
endpoint.  Systematic reviews fulfilling the PICO criteria were selected in the preliminary 157 
search for further analysis.  158 
 159 
Quality assessment  160 
All studies included at full text stage were randomized control trials and a quality assessment 161 
for each study was carried out using the Cochrane risk of bias tool13. To assess the quality of 162 
any systematic reviews, the Documentation and Appraisal Review Tool (DART) was used14.  163 
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There is no standardized tool available for quality assessing case series, and these studies 164 
were assessed on criteria suggested by the Agency for Healthcare Research and Quality 165 
(AHRQ)15. 166 
 167 
Intervention Fidelity Assessment 168 
During full text review, the methodology was examined (including online supplementation 169 
where available) to determine whether the investigators had systematically excluded common 170 
alternative causes of cough in their patient population prior to the intervention.   171 
 172 
Grading Recommendations  173 
Each recommendation is graded for the strength of the recommendation and quality of 174 
evidence, as is the case for all CHEST guidelines12. The strength of recommendation is graded 175 
as either strong (grade 1; likely to apply to almost all patients) or weak (grade 2; conditional 176 
and only applying to selected patients).  This grading is based on the quality of the evidence, 177 
the balance of risk versus potential benefit, the acceptability to patients and resource 178 
considerations (for example: cost, availability, practicality / burden).  The overall quality of 179 
evidence for each recommendation is graded as high (grade A), moderate (grade B) or low 180 
(grade C).  A structured consensus-based Delphi approach was used to provide expert advice 181 
on guidance statements 16. In this regard, for a recommendation or suggestion to be approved 182 
by the Expert Cough Panel, 75% of the eligible Panel members had to vote and 80% of those 183 
voting had to strongly agree or agree with the statement. All panelists had the opportunity to 184 
vote during the Delphi exercise; none were recused because of any conflicts of interest (e-185 
Table 1).  A patient representative who is a member of the Cough Panel provided patient-186 
centered input for this guideline and approved of the suggestions contained herein. 187 
 188 
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RESULTS  189 
Figure 1 summarizes the results of the systematic review.  The majority of publications were 190 
excluded by title or abstract alone, because they did not meet the inclusion criteria (702 of the 191 
723 identified by the literature search).  Twenty-six full text publications were reviewed and a 192 
further 16 excluded. The most common reasons for exclusion at this stage were studies that 193 
did not use a standardized or validated cough end-point or reviews that were non-systematic.  194 
Finally, 3 systematic reviews that met our inclusion criteria were excluded because the only 195 
relevant studies they contained were already included in our review17-19.  Three papers 20-22 196 
met the inclusion criteria but were published after the initial search and were subsequently 197 
included on agreement of all the authors of the expert panel report. This process resulted in 10 198 
studies included in this review (table 2).  Of these, 5 concerned idiopathic pulmonary fibrosis, 199 
3 investigated the use of inhaled corticosteroids in pulmonary sarcoidosis and 2 investigated 200 
immunosuppressive therapies in scleroderma-related ILD. 201 
 202 
Quality Assessment. 203 
In general, the study quality was high in the trials selected for inclusion in the systematic 204 
review.  In the 8 RCTs included, the risk of bias was unclear in four of the studies in the area 205 
of selection (table 3).  A high risk of bias was identified in one study in selective outcome 206 
reporting 23.  This paper presents further, new analyses of the patients reported in an earlier 207 
study 24 and a post-hoc subgroup analysis. The methodology used to determine the subgroups 208 
was unclear and this paper was therefore categorized as high risk of selective outcome 209 
reporting.  The two observational studies included have an inherent risk of bias, having no 210 
placebo group and therefore have to be interpreted with caution.  211 
 212 
Diagnosis of cough.  213 
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Cough in a patient with interstitial lung disease may be due to their underlying lung disease.  214 
However, because chronic cough occurs so commonly in the general population 25, it is likely 215 
that in some cases other diseases may be responsible for the cough in patients with ILD 216 
(asthma, eosinophilic bronchitis, upper airway causes, drug therapy) or that cough may be 217 
unexplained.  Patients with some ILDs are commonly treated with immunosuppressive 218 
therapies, and therefore, infectious causes should also be considered.   219 
 220 
Only one of the included studies 26 reported using a standardized diagnostic protocol to assess 221 
cough prior to their intervention, otherwise it is unclear whether alternative causes of cough 222 
were fully excluded (e.g. asthma, upper airway cough syndrome).   In 4 studies 23,27-29, cough 223 
was not a major focus of the study and was only examined as a secondary or tertiary end-point 224 
and often as part of a composite symptom score, so it is unlikely a cough diagnostic protocol 225 
was used.  Horton et al and Birring et al did complete an assessment for identifiable causes of 226 
cough but details of this assessment was not recorded.  In Theodore, et al’s study 30, it is 227 
possible that enrolled patients had been assessed; however, this was not reported.   228 
 229 
Suggestion 1.  For patients with ILD who present with a troublesome cough, we suggest 230 
that patients be assessed for progression of their underlying ILD, or complications from 231 
immunosuppressive treatment (e.g. drug side effect, pulmonary infection) and also be 232 
considered for further investigation / treatment trials for their cough according to 233 
guidelines for acute, subacute and chronic cough.  (Ungraded Consensus- Based 234 
Statement) 235 
 236 
Cough in IPF.  237 
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While the major trials of pirfenidone 24,31,32 and nintedanib 33 have not reported data on the 238 
impact of treatment on cough (table 4), Azuma et al 23 used data from an earlier Japanese 239 
pirfenidone trial 24 to report on the impact of pirfenidone on cough in IPF.  These data were 240 
not published in the initial study, but cough was included as part of a composite symptoms-241 
based tertiary endpoint, together with dyspnea.  Azuma et al report no significant difference 242 
overall in cough severity between the treatment arms (low and high dose pirfenidone) and 243 
placebo.  A recent study by van Manen et al 22 investigated the effect of pirfenidone on IPF 244 
associated cough using validated cough outcome tools (Leicester Cough Monitor and 245 
Leicester Cough Questionnaire).  There was a 34% reduction in objective cough frequency 246 
and a clinically significant improvement in cough-related quality of life. The limitation of this 247 
study was the lack of a control group. 248 
 249 
Horton et al assessed cough as a primary endpoint in patients with cough and IPF 34.  This was 250 
a crossover trial where all patients received 12 weeks of treatment with thalidomide 50mg 251 
daily, increasing in all but 1 patient to 100 mg if there was no improvement in cough after 2 252 
weeks. All patients receiving thalidomide routinely received sodium docusate and vitamin B 253 
supplementation. The trial recruited small numbers of patients (24 patients, of whom 20 254 
completed the trial). There was a statistically significant improvement in CQLQ score (a 255 
validated quality of life questionnaire for cough) (decreased 11.37 points, p<0.001), cough 256 
VAS (decreased by 31.2mm, p<0.001) and the SGRQ (decreased 11.7 points, p=0.001).   257 
 258 
The side effect profile of thalidomide is an obvious concern, including its potential 259 
teratogenicity in women of childbearing age.  Significantly more patients receiving 260 
thalidomide than placebo reported adverse events (77% vs 22%, p=0.001).  The commonest 261 
side effects were constipation, dizziness and malaise. There were no serious adverse events 262 
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during treatment.  Three patients required a dose reduction and the four withdrawals from the 263 
study were due to lack of interest (n=1) or disease progression and inability to return for study 264 
visits (n=3). Despite most patients experiencing side effects, all participants accepted the offer 265 
of continuing thalidomide treatment at the end of the trial. 266 
 267 
Based on this evidence, the authors made a recommendation to the CHEST Expert Cough 268 
Panel that thalidomide be considered in those with IPF and chronic cough where alternative 269 
causes of cough were ruled out (Grade 2c).  Only 67% of the panel voted in favor of this 270 
recommendation, and so it failed to pass and was removed (an approval score of 80% is 271 
required).  It is likely that the practical barriers to prescribing Thalidomide in many countries, 272 
side effects and the limited evidence from a single, small trial were concerns amongst the 273 
CHEST Expert cough panel. The potential of thalidomide should be further investigated. 274 
 275 
A recent proof of concept study investigated the efficacy of a novel inhaled cromolyn sodium 276 
formulation (PA101) in IPF patients with chronic cough 20.  PA101 is a high concentration 277 
Cromolyn formulation delivered via a high efficiency eFlow nebulizer that achieves 278 
significantly higher drug deposition in the lung compared to existing formulations. There was 279 
a 31% decrease in daytime mean cough frequency (the primary outcome measure) at day 14 280 
with treatment when adjusted for placebo, but no statistically significant change in cough 281 
specific quality of life (measured by LCQ) or cough severity (measured by VAS score).  The 282 
drug was well tolerated with no severe or serious adverse events reported.  PA101 Cromolyn 283 
is not currently available to prescribe and further studies investigating its efficacy are awaited.   284 
 285 
 286 
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Proton Pump Inhibitors (PPIs) have long been used in IPF, and have been recommended in 287 
the 2015 American Thoracic Society IPF guidelines35.  This was a conditional 288 
recommendation and was based on two observational studies suggesting a slower decline in 289 
Vital Capacity in IPF patients taking PPI therapy.  Kilduff et al 26 investigated the efficacy of 290 
high dose PPI and H2 receptor antagonist for 8 weeks in a small group of 18 patients with 291 
IPF. They assessed cough and gastro-esophageal reflux (GERD) objectively with esophageal 292 
pH and impedance testing and cough monitoring.  This was an uncontrolled study, but there 293 
was no change in objective cough counts with PPI despite a decrease in acid reflux events.   294 
This finding is in keeping with current evidence in unexplained chronic cough, where no 295 
benefit in cough severity or quality of life has been observed with high dose esomeprazole in 296 
RCTs 36,37.  The CHEST unexplained chronic cough guideline therefore recommends against 297 
using PPIs in patients with a negative workup for acid gastro-esophageal reflux. 298 
 299 
Suggestion 2. For patients with IPF, chronic cough and a negative workup for acid 300 
gastroesophageal reflux, we suggest that proton pump inhibitor therapy not be  301 
prescribed.  (Ungraded Consensus- Based Statement)  302 
 303 
 304 
Cough in Sarcoidosis 305 
Three trials investigating inhaled steroids in sarcoidosis were included (table 4).  The type of 306 
patients included in each study differed, as did the dose of inhaled steroid used.  Baughman et 307 
al studied 22 patients with acute sarcoidosis 27.  All patients were given concomitant oral 308 
steroids according to a standardized protocol.  Ten patients were randomized to also take 309 
880µg of fluticasone twice a day for 48 weeks, while the other 12 took a placebo inhaler.  310 
Cough was evaluated in a systematic way, although not using a validated cough tool.  Cough 311 
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was reported as ‘better’ in more patients in the treatment arm (8 out of 10 in the treatment arm 312 
versus 6 out of 11 in the placebo arm); however, there was no statistically significant 313 
difference (p=0.36).  There was no reduction in oral steroid requirements in the treatment arm.    314 
 315 
DuBois et al also investigated the efficacy of inhaled fluticasone28; but, in contrast, in patients 316 
with established sarcoidosis (> 1 year from time of diagnosis) and at a slightly higher dose 317 
compared to Baughman et al (2000 mcg daily versus 1760 mcg daily). Seventy-five percent of 318 
patients were concomitantly taking oral prednisolone; but this was balanced across the 319 
placebo and treatment groups.  Cough was evaluated by a 4-point severity scale.  This study 320 
also recruited a relatively small number of patients (n=43), and although all patients reported 321 
a decrease in cough severity at the end of the trial there was no significant difference between 322 
the fluticasone and placebo arms.   323 
 324 
Milman et al conducted a study in 1994 29 to investigate inhaled budesonide in established 325 
sarcoidosis.  The number of subjects recruited was small, with 29 patients enrolled of whom 326 
14 were treated with budesonide.  There was no difference in cough severity, assessed with a 327 
4-point scale, between the treatment and placebo arms (p=0.87).  In the small subgroup on 328 
oral prednisolone (eight patients) there was no significant difference in the change in oral 329 
prednisolone dose with treatment versus placebo.  330 
 331 
Suggestion 3. For patients with pulmonary sarcoidosis, we suggest that inhaled 332 
corticosteroids should not be routinely prescribed to treat the chronic cough.  (Grade 333 
2C).  334 
 335 
Cough in Scleroderma-related ILD.  336 
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The only studies included relating to connective tissue disease both concern Scleroderma-337 
related ILD.  Theodore et al 30 reported cough data from the Scleroderma Lung Study 10 that 338 
randomized 158 patients to receive either cyclophosphamide or placebo for one year (with a 339 
further 12 months follow up).  A cough index, (which included a score of severity, frequency 340 
and presence of phlegm) was assessed at baseline and 3 monthly intervals.  Patients with 341 
cough (73%) were more likely to have severe lung disease (established with TLCO and CT 342 
scans) and more diffuse scleroderma.  The change in cough index with cyclophosphamide 343 
therapy compared to placebo was not significantly different.  There was a trend for greater 344 
improvement in reported cough frequency in the treatment group, but this did not reach 345 
statistical significance (p=0.56).   346 
 347 
Tashkin et al reported cough data from the Scleroderma Lung Study II 11 that randomized 142 348 
patients to either cyclophosphamide for 1 year followed by placebo for one year, or to 349 
mycophenalate for 2 years.  Given the interesting findings concerning cough in the first 350 
scleroderma lung study, the investigators included the LCQ as a secondary outcome measure.  351 
The presence of ‘frequent cough’ was determined by the responses to 2 questions in the St 352 
George’s questionnaire.  The paper reported the number of frequent coughers and LCQ scores 353 
from both treatment arms combined and compares these to pre-treatment scores, not against 354 
placebo. There was a decrease in the number of patients who reported frequent cough (from 355 
61.7% to 45.7%, p = .0051); but there was no significant difference in the LCQ scores.   356 
 357 
The Tashkin paper also reported an association between the presence of GERD-related GI 358 
symptoms and frequent cough. Of those patients with frequent cough, 77% reported GERD-359 
related GI symptoms at baseline compared with 59% of non-coughers (p= 0.025).  In the 360 
small number of patients in whom GERD had resolved by 24 months (n=8), there was a 361 
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clinically significant improvement in mean LCQ score (from 14.3 to 17.9). In contrast, LCQ 362 
scores were unchanged in patients who had persistent GERD at the end of the study.   363 
 364 
Refractory or Unexplained Cough in ILD.   365 
Patients with ILD and refractory cough have severely impaired quality of life 2.  In view of the 366 
limited treatment options for cough, the authors felt it was reasonable to manage such patients 367 
according to the CHEST unexplained cough guideline, particularly in those with advanced 368 
disease and poor quality of life. 38 369 
 370 
One treatment option recommended in the CHEST unexplained cough guideline is 371 
multimodality speech pathology therapy (SPT) 39 that has been reported to decrease objective 372 
cough frequency and improve quality of life in patients with unexplained chronic cough 40.  A 373 
similar efficacy has been reported for physiotherapy, speech and language therapy 374 
intervention (PSALTI) 41. These therapies include educating patients about cough, teaching 375 
cough suppression techniques, vocal hygiene and psychoeducational counseling.  Gabapentin, 376 
a neuromodulator, is also recommended, and in one RCT it decreased cough severity, 377 
frequency and improved quality of life in patients with refractory chronic cough 42.  Side 378 
effects were experienced by 10 of the 32 patients in the treatment group and were most 379 
commonly confusion, dizziness, dry mouth, fatigue and nausea.  There was a clinically and 380 
statistically significant improvement in the mean LCQ score of 1.8 adjusted for placebo 381 
effect.  A more recent study combined the use of pregabalin and speech therapy and found a 382 
larger improvement in LCQ and cough VAS compared to speech therapy alone, suggesting a 383 
combined approach may offer additional benefit 43. 384 
 385 
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Suggestion 4. For patients with ILD and refractory chronic cough, we suggest trials of 386 
therapies recommended for patients with unexplained chronic cough according to the 387 
CHEST guidelines, with treatments such as gabapentin and multimodality speech 388 
pathology therapy, or entering into clinical trials if available. (Ungraded Consensus- 389 
Based Statement) 390 
 391 
This review found no studies that met the inclusion criteria on the use of opiates for 392 
management of chronic cough in ILD patients.  There is a single RCT investigating slow 393 
release morphine (5mg twice daily) in refractory chronic cough patients 44.  This was a 394 
positive study with a significant improvement in quality of life (a mean increase of 3.2 points 395 
in the LCQ score).  The most common side effects were constipation and drowsiness; 396 
however, the drug was well tolerated and no patients withdrew from the study due to adverse 397 
events.  Opiates were not recommended by the CHEST Cough Panelists for unexplained 398 
cough, because such a recommendation narrowly failed the guideline acceptance voting 399 
threshold of 80%.  Nevertheless, the authors of this guideline agree that opiates should be 400 
considered for ILD patients with intractable cough when the cough has a substantial impact on 401 
quality of life and when all alternative treatments have failed. Low dose opiates may be 402 
helpful for symptomatic relief, and this will be particularly appropriate in the palliative care 403 
setting.  There are guidelines for the use of opiates for symptomatic relief of dry cough in 404 
patients receiving palliative care 45; and, in the US, the CDC has published primary care 405 
physician guidelines for opiate use in the treatment of chronic pain that includes helpful 406 
advice regarding the potential harms of opiate use and managing risk 46.     407 
 408 
Suggestion 5. For patients with chronic cough due to ILD, when alternative treatments 409 
have failed and the cough is adversely affecting their quality of life, we suggest that 410 
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opiates be recommended for symptom control in a palliative care setting, with 411 
reassessment of the benefits and risks at 1 week and then monthly before continuing.  412 
(Ungraded Consensus- Based Statement) 413 
 414 
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DISCUSSION 416 
 417 
Diagnosis 418 
Interstitial lung diseases are a broad range of conditions that can affect the airways, lung 419 
parenchyma and pulmonary vasculature.  The involvement of any of these compartments can 420 
lead to development of cough.  Cough in patients with ILD can also be caused by ILD drug 421 
therapy, infections and the presence of co-morbid conditions, such as GERD, upper airways 422 
disease and asthma.   It can therefore be challenging to determine the cause of a cough in a 423 
patient with ILD.  The approach to investigating patients with ILD-associated cough needs to 424 
be individualized to the patient, and therefore a general approach such as that suggested in 425 
Figure 2 has limitations and should be used only as a guide.  ILD is likely to be the cause of 426 
cough in a patient with evidence of disease progression, temporal association between onset 427 
of cough and disease progression and a favorable response to ILD therapy.  428 
  429 
When cough persists, other causes should be investigated as per the CHEST Chronic Cough 430 
Guidelines, specifically evaluating patients for the presence of asthma, non-asthmatic 431 
eosinophilic bronchitis, upper airways cough syndrome due to a variety of rhinosinus 432 
conditions, and/or GERD 38. If a cause is not established and the patient is significantly 433 
troubled by their cough, in the opinion of this guideline group, it is reasonable to follow the 434 
CHEST Unexplained Cough Guideline approach for managing cough patients because it is 435 
possible that some patients with ILD and an unexplained cough have dysfunctional cough 436 
sensory nerves 47. The term ‘cough hypersensitivity syndrome’ has been proposed to address 437 
such patients 48. In IPF, there is evidence of increased cough reflex sensitivity to both 438 
capsaicin and nerve derived mediator substance P and increased levels of nerve growth factor 439 
have been reported in the airways of patients with IPF 49.  440 
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 441 
Therapy 442 
The approach to treating cough depends on a number of factors that include the type of ILD, 443 
the availability of effective treatments for ILD, the risk/benefit profile of ILD and anti-tussive 444 
treatments and the presence of co-morbid conditions that can cause cough.  When ILD is the 445 
suspected cause of cough, treatment for the underlying ILD should be considered on an 446 
individual basis, particularly in patients with clear evidence of disease progression.  447 
 448 
IPF 449 
In IPF, anti-fibrotic therapy with pirfenidone and nintedanib should be prescribed according 450 
to ATS/ERS Guidelines, and not specifically for cough 35.  It is possible that anti-fibrotic 451 
therapy may reduce the severity of cough as suggested by the findings of an uncontrolled 452 
study 22 but this needs confirmation in larger clinical trials.  453 
  454 
There are no controlled studies that have evaluated the use of systemic corticosteroids for IPF-455 
associated cough.   The efficacy of corticosteroids for suppressing cough was evaluated in an 456 
open label study of 6 patients by Hope-Gill et al, which did report a reduction in cough; 457 
however, this did not meet our review inclusion criteria 49. Corticosteroids in IPF (in 458 
combination with azathioprine and N-Acetyl-Cysteine; “triple therapy”) have been associated 459 
with increased mortality compared to placebo 50 and the use of corticosteroids in IPF should 460 
therefore be limited to patients that may be experiencing an exacerbation of IPF or who have 461 
co-existing asthma or eosinophilic bronchitis.   462 
 463 
Thalidomide has been investigated in IPF-associated cough in a single-center trial that 464 
included a small number of patients34.  Thalidomide led to a significant improvement in 465 
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quality of life. The mechanism of action is thought to be anti-inflammatory, and possibly 466 
reduced cough sensory nerve activity 51,52  Thalidomide was, however, associated with 467 
significant side-effects 34. While Thalidomide is not suggested for use in IPF-associated 468 
cough, the Committee does encourage further study of Thalidomide for cough because it 469 
might be helpful.  470 
 471 
A recent pilot study of a novel formulation of inhaled cromolyn sodium (PA101) showed 472 
promise 20.  There was a >30% reduction in objective cough frequency between the treatment 473 
and placebo periods that is likely to be clinically significant. Although there was no 474 
significant change in the subjective cough severity and quality of life measures with 475 
treatment, the study was not powered to detect these and the treatment duration was short.  476 
The drug was well tolerated in this pilot study.  A larger trial with a longer treatment period is 477 
needed to further assess its efficacy. 478 
 479 
Sarcoidosis 480 
In sarcoidosis, three trials of inhaled corticosteroids did not demonstrate a significant 481 
reduction in cough.   The findings of the trials by duBois et al and Baughman et al did report 482 
trends towards improvement in cough27,28.  Further trials are needed to clarify the efficacy of 483 
inhaled corticosteroids, ideally in carefully selected patients with active, airway-centered 484 
disease and a clinically significant cough.    485 
 486 
Scleroderma 487 
Two connective tissue disease ILD studies met the inclusion criteria of this Guideline.   They 488 
evaluated immunosuppressive therapy in Scleroderma-associated ILD 21,30. Both studies 489 
demonstrated an association between cough and the severity of ILD.   Theodore et al found no 490 
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significant improvement in cough with cyclophosphamide.  Tashkin et al, however, did report 491 
a decrease in subjective cough frequency with treatment (cyclophosphamide or 492 
mycophenolate), but this was not associated with a significant improvement in quality of life.  493 
The clinical significance of these therapies is therefore not clear and we suggest that 494 
immunosuppressive therapy be prescribed for the underlying lung disease, rather than 495 
specifically for cough.   Further trials in scleroderma-associated ILD are needed, with cough 496 
as the primary focus.    497 
 498 
Gastro-esophageal reflux Disease 499 
GERD is highly prevalent in both patients with ILD, such as IPF and scleroderma-associated 500 
ILD and is therefore a potential cause of cough.  There were no randomized controlled trials 501 
of proton pump inhibitor (PPI) therapy in ILD-associated cough.   There was a small open 502 
label study of high dose acid suppression therapy in IPF cough that did utilize validated 503 
objective and subjective cough end-points 26; however, there was no improvement in cough 504 
with PPI therapy.  In patients with unexplained chronic cough and no ILD, two randomized 505 
controlled trials did not demonstrate anti-tussive efficacy 36,37. The CHEST Unexplained 506 
Chronic Cough Guidelines therefore recommended that, in patients with a negative work-up 507 
of acid gastro-esophageal reflux that included esophageal pH monitoring, PPI therapy should 508 
not be prescribed 38.  A similar approach in IPF cough seems reasonable.   In patients with 509 
scleroderma-associated ILD, esophageal dysfunction is a key feature of the disease and 510 
improvement in cough has been associated with improvements in GERD in the Tashkin 511 
study21.  Therefore, a thorough approach investigating both acid and non-acid reflux in 512 
scleroderma-associated ILD is reasonable until studies that guide best management become 513 
available. 514 
 515 
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Other Antitussive therapies: Neuromodulators, Speech/physiotherapy and Opiates 516 
The severity of cough in ILD, particularly IPF, and its impact on quality of life warrants 517 
consideration of further anti-tussive therapy options.   In unexplained chronic cough, there are 518 
several randomized controlled trials that support the use of neuromodulator drugs, such as 519 
gabapentin and pregabalin 42,43, morphine 44 and non-pharmacological interventions such as 520 
speech pathology therapy 39,40 and Physiotherapy and Speech and Language Intervention 521 
(PSALTI). 41 There are no studies that evaluated the efficacy of these therapies in ILD, and 522 
they are urgently needed.   The Guideline Panel acknowledged the paucity of evidence for use 523 
of general anti-tussive therapy in ILD, but recommended that they should be considered 524 
because of the lack of availability of treatment options, and for use in a palliative care setting.  525 
Opiates are likely the most controversial of these treatment options, due to concerns about 526 
safety, and the potential for abuse and addiction. Indeed, morphine narrowly missed the 80% 527 
voting endorsement requirement of the ACCP Unexplained Cough Guidelines due to such 528 
concerns 38.  However, given the severity of lung disease and the poor prognosis associated 529 
with many ILDs, the panel felt that morphine should be considered as a potential treatment for 530 
ILD cough when quality of life is severely impacted.  It is already used to some extent by 531 
clinicians to relieve both cough and dyspnea in ILD and for IPF patients with debilitating 532 
cough 53. 533 
 534 
SUMMARY OF SYSTEMIC REVIEW RESULTS AND ITS LIMITATIONS 535 
The present systemic review evaluated ten trials that investigated therapeutic interventions in 536 
ILD-associated cough.  Cough was often not the primary focus of these studies, and was 537 
reported in retrospective analyses.  The sample sizes were relatively small, and a variety of 538 
outcome assessments were used, not all of which were adequately validated. None of the 539 
interventions have been replicated in other RCTs.   It is likely that there was heterogeneity in 540 
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the patient population under study that restricts the general reliability of the results.   541 
Intervention fidelity is recognized as a key aspect in the diagnosis of unexplained chronic 542 
cough and this factor was incompletely reported in the studies included in this review that 543 
indicates a possibility for indication-bias in the studies evaluated.   These aspects of study 544 
design limit the strength of the conclusions. 545 
 546 
FUTURE DIRECTIONS 547 
A better estimate of the prevalence, severity and predictors of cough in ILD is needed in 548 
larger population studies. Cough may be a potential biomarker in ILD, and therefore its 549 
potential to assess disease severity and guide prognosis should be evaluated.   There is a clear 550 
need for randomized controlled trials of anti-tussive therapy in ILD.  Validated cough 551 
outcome measures such as objective cough monitoring, visual analogue severity scales and 552 
quality of life questionnaires, such as the CQLQ and LCQ should be used 54-56.   Registries for 553 
patients with ILD, such as IPF, should record the presence and severity of cough, and this can 554 
be done with very simple tools such as the VAS or the Borg scale.  There are now numerous 555 
targets identified for novel anti-tussive therapies for unexplained cough.  The antagonist of the 556 
P2X3 sensory nerve ion channel is one of the most promising and advanced in development.   557 
A randomized controlled trial of a P2X3 antagonist in IPF-associated cough has been 558 
completed, but not reported 57.  The novel Cromolyn formulation PA101 shows promise in a 559 
proof of concept trial but needs further evaluation 20.  Other anti-tussive targets include the 560 
Neurokinin-1, TRPV4 and alpha-7 nicotinic receptors 58-60. Further studies of Thalidomide 561 
and similar drugs are also warranted. 562 
 563 
 564 
 565 
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 566 
 567 
CONCLUSIONS 568 
Cough associated with ILD can be due to underlying lung disease, and co-morbid conditions 569 
such as upper airway disease or GERD.  In some patients it remains unexplained. The 570 
approach to managing ILD-associated cough needs to be individualized for the patient.    571 
Further clinical trials of neuromodulator therapies and speech pathology/physiotherapy-based 572 
cough suppression are needed.   573 
 574 
 575 
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 670 
Table 1. Eligibility criteria 671 
Criteria Study requirements 
Inclusion ▪? Published any time prior to time of search (February 2016) 
▪? English language  
▪? Any study design, case series (>10 subjects) 
Population ▪? Age > 18 years 
▪? Diagnosis of ILD, IPF or Sarcoidosis 
Intervention ▪? Any pharmacological intervention or non-pharmacological 
intervention 
Control / 
comparison 
▪? Usual care / standard therapy or placebo (if applicable to study 
design) 
Outcome  ▪? Assessment of cough (measured using validated/standardized tool) 
 672 
 673 
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Table 2. Study characteristics  
Study Study design Anatomical 
work up for 
chronic cough 
Duration Intervention Number randomised 
[intervention arm ; 
placebo arm] 
IPF 
Azuma 2011 Post-hoc analysis of a multicenter 
randomized double blind placebo 
controlled trial 
No 12 months Pirfenidone 1200mg or 
1800mg/day 
275 [166 ; 109] 
Horton 2012 Randomized double blind placebo 
controlled crossover 
No 12 weeks Thalidomide 100mg 24* 
 
Kilduff 2014 Cohort study Yes 8 weeks High dose PPI (omeprazole 
40mg bd or lansoprazole 30mg 
bd) plus ranitidine 300mg nocte 
18 
Birring 2017 Multicenter, randomized, double 
blind, placebo controlled, 2-cohort, 
2-period cross-over trial 
 
Yes 14 days Inhaled cromolyn sodium 
(PA101) via eFlow nebulizer 
40mg tds 
24* 
 
                                                                                                                             
 
Van Manen 2017 Multi-center, prospective, 
observational study 
No 12 weeks Pirfenidone 2403mg/day** 43 
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*Cross over trial design 
** Communication with first author. Target dose; patients were up titrated from 801mg/day starting dose over a 2 week period.  
*** This study pooled the cough data from both treatment arms
SARCOID 
Milman 1994 Randomized double blind placebo 
controlled 
No 12 months Inhaled budesonide 1.2 or 
2.0mg/day 
21 [9 ; 12] 
Du Bois 1999 Two center randomized double 
blind placebo controlled  
No 6 months intervention 
+ 2 months follow up 
Inhaled fluticasone 2mg /day 43 [21 ; 22] 
Baughman 2002 Multicenter randomized double 
blind placebo controlled  
No 48 weeks Inhaled fluticasone 880mcg bd 22 [10 ; 12] 
SCLERODERMA 
Theodore 2012 Randomized double blind placebo 
controlled 
No 12 months Oral cyclophosphamide 
2mg/kg monthly 
158 [79 ; 79] 
Tashkin 2017 Multicenter randomized double 
blind trial, 2 treatment arms 
No 24 months Mycophenylate target dose 
1500mg bd for 24 months 
OR 
Cyclophosphamide target dose 
2mg/kg/day for 12 months then 
placebo 12 months 
 
142*** 
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Table 3. Risk of bias - RCTs 
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L U L U L U L L Random sequence generation (selection bias) 
U U L U L U L L Allocation concealment (selection bias) 
L L L L L L L L Blinding of participants and personnel (performance bias) 
L L L L L L L L Blinding of outcome assessment (detection bias) 
L L L L L U L L Incomplete outcome data addressed (attrition bias) 
H L L L L L L L Selective outcome reporting (reporting bias) 
L L L L L L L L Other bias 
 
 
H = high risk of bias 
L = low risk of bias 
U = unclear risk of bias 
n/a = not applicable  
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Table 4. Treatment Effects  
 
Cough 
severity 
Cough 
frequency 
(subjective) 
Cough 
frequency 
(objective) 
Cough QoL 
Pirfenidone in IPF 
Azuma et al 2011 + n/a n/a n/a 
Van Manen et al 2017 + n/a + + 
Thalidomide in IPF 
Horton et al 2012 + n/a n/a + 
Acid suppression in IPF 
Kilduff et al 2014 n/a n/a - n/a 
Cromolyn in IPF 
Birring et al 2017 - n/a + - 
Inhaled steroid in pulmonary sarcoidosis 
Milman et al 1994 - n/a n/a n/a 
Du Bois et al 1999 - n/a n/a n/a 
Baughman et al 2002 - n/a n/a n/a 
Oral cyclophosphamide in SSc-ILD 
Theodore et al 2012 - - n/a n/a 
Tashkin et al 2017 n/a + n/a - 
Mycophenylate in SSc-ILD 
Tashkin et al 2017 n/a + n/a - 
 
 
+  statistically significant improvement 
-  no statistically significant difference 
n/a not measured
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e-Appendix 1: Search terms 
COUGH_ILD, Sarcoidosis, Bronchiolitis_ Search Strategies 
 
Question 1:  In a patient with ILD and cough, when should ILD be considered a 
cause of cough? 
 
Question 2:  Is there evidence of clinically relevant treatment effects for therapies 
for cough in ILD, Sarcoidosis and Bronchiolitis? 
 
Limits (when available) were generally: 
 English language 
 Humans 
 Adult (age 19 and older ) 
 No editorials, comments or letters 
 No date limits (full date ranges of individual databases)  
 
 
Systematic Review Searches 
 
PubMed – The subset filter of “AND systematic[sb]” was applied to the results of the 
PubMed searches (both questions 1 and 2). With this method, 15 systematic reviews or 
guidelines were identified.  Among them were Cochrane reviews (also indexed in PubMed).  
The rest were systematic reviews or guidelines published by non-Cochrane groups. 
 
Cochrane Database of Systematic Reviews (Wiley – created in 1995, updated 
monthly) Additional searches were performed directly in the Cochrane Database of 
Systematic Reviews for both questions 1 and 2, using the same search configurations as for 
the CINAHL searches. 
Of the reviews retrieved for both questions 1 and 2, the majority were focused on children.  
Only one relevant review (an update) was identified that was not already in the group. 
Systematic reviews were included in a group folder in the Question 2 (therapy) library.   
 
 
PubMed Searches:  (open access)  - produced by the U.S. National Library of 
Medicine (includes indexed MEDLINE records) – 1950s to present 
 
Question 1: 
cough AND ("Lung Diseases, Interstitial"[Mesh:NoExp] OR interstitial lung disease*[tiab] OR 
"Alveolitis, Extrinsic Allergic"[Mesh:NoExp] OR extrinsic allergic alveolitis[tiab] OR "Anti-
Glomerular Basement Membrane Disease"[Mesh] OR anti-glomerular basement membrane 
disease[tiab] OR "Histiocytosis, Langerhans-Cell"[Mesh] OR Langerhans-cell 
histiocytosis[tiab] OR "Idiopathic Interstitial Pneumonias"[Mesh]  OR idiopathic interstitial 
pneumonia*[tiab]  OR organizing pneumonia[tiab] OR cryptogenic fibrosing alveolitis[tiab] 
OR non-specific interstitial pneumonia[tiab] OR "Radiation Pneumonitis"[Mesh] OR radiation 
pneumonitis[tiab] OR "Sarcoidosis, Pulmonary"[Mesh] OR pulmonary sarcoidosis[tiab] OR 
hypersensitivity pneumonitis[tiab] OR sarcoidosis OR obliterative bronchiolitis[tiab] OR 
bronchiolitis obliterans[tiab] OR cryptogenic obliterative bronchiolitis[tiab] OR acute 
bronchiolitis[tiab] OR diffuse pan-bronchiolitis[tiab] OR follicular bronchiolitis[tiab] OR 
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aspiration bronchiolitis[tiab] OR }desquamative interstitial pneumonia}[tiab]) AND (etiology 
OR cause OR epidemiology[mh] OR epidemiology[tiab] OR prevalence OR diagnosis OR 
assessment[tiab] OR investigation) NOT (editorial[pt] OR letter[pt] OR comment[pt])  
Filters: Humans; English; Adult: 19+ years 
 
Question 2: 
cough AND ("Lung Diseases, Interstitial"[Mesh:NoExp] OR interstitial lung disease*[tiab] OR 
"Alveolitis, Extrinsic Allergic"[Mesh:NoExp] OR extrinsic allergic alveolitis[tiab] OR "Anti-
Glomerular Basement Membrane Disease"[Mesh] OR anti-glomerular basement membrane 
disease[tiab] OR "Histiocytosis, Langerhans-Cell"[Mesh] OR Langerhans-cell 
histiocytosis[tiab] OR "Idiopathic Interstitial Pneumonias"[Mesh]  OR idiopathic interstitial 
pneumonia*[tiab]  OR organizing pneumonia[tiab] OR cryptogenic fibrosing alveolitis[tiab] 
OR non-specific interstitial pneumonia[tiab] OR "Radiation Pneumonitis"[Mesh] OR radiation 
pneumonitis[tiab] OR "Sarcoidosis, Pulmonary"[Mesh] OR pulmonary sarcoidosis[tiab] OR 
hypersensitivity pneumonitis[tiab] OR sarcoidosis OR obliterative bronchiolitis[tiab] OR 
bronchiolitis obliterans[tiab] OR cryptogenic obliterative bronchiolitis[tiab] OR acute 
bronchiolitis[tiab] OR diffuse pan-bronchiolitis[tiab] OR follicular bronchiolitis[tiab] OR 
aspiration bronchiolitis[tiab] OR }desquamative interstitial pneumonia}[tiab]) AND 
(treatment OR therapy OR drug therapy OR thalidomide OR corticosteroids OR 
cyclophosphamide OR salbutamol OR proton pump inhibitors OR immunosuppressants OR 
pirfenidone OR nintendanib OR erythromycin OR macrolides OR muscarinic antagonists OR 
"beta agonist"[tiab]) NOT (editorial[pt] OR letter[pt] OR comment[pt])  
Filters: Humans; English; Adult: 19+ years  
  
 
Scopus Searches (Elsevier) - includes EMBASE records:  1823 to present 
 
Question 1: 
TITLE-ABS-KEY(cough AND ( 
 OR {extrinsic allergic alveolitis}28-30 OR {anti-glomerular basement membrane disease} OR 
{Langerhans-cell histiocytosis} OR {idiopathic interstitial pneumonia} OR {organizing 
pneumonia} OR {cryptogenic fibrosing alveolitis} OR {non-specific interstitial pneumonia} 
OR {radiation pneumonitis} OR {pulmonary sarcoidosis} OR {hypersensitivity pneumonitis} 
OR sarcoidosis OR {obliterative bronchiolitis} OR {bronchiolitis obliterans} OR {cryptogenic 
obliterative bronchiolitis} OR {acute bronchiolitis} OR {diffuse pan-bronchiolitis} OR 
{follicular bronchiolitis} OR {aspiration bronchiolitis} OR {desquamative interstitial 
pneumonia}) AND (etiology OR cause OR epidemiology OR prevalence OR diagnosis OR 
assessment OR investigation)) AND (adult OR adolescent)) AND ( LIMIT-TO(DOCTYPE,"ar" ) 
OR LIMIT-TO(DOCTYPE,"re" ) OR LIMIT-TO(DOCTYPE,"cp" ) OR LIMIT-TO(DOCTYPE,"ip" ) ) 
AND ( LIMIT-TO(LANGUAGE,"English" ) )  
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Question 2: 
TITLE-ABS-KEY(cough AND ({interstitial lung disease} OR {extrinsic allergic alveolitis} OR 
{anti-glomerular basement membrane disease} OR {Langerhans-cell histiocytosis} OR 
{idiopathic interstitial pneumonia} OR {organizing pneumonia} OR {cryptogenic fibrosing 
alveolitis} OR {non-specific interstitial pneumonia} OR {radiation pneumonitis} OR 
{pulmonary sarcoidosis} OR {hypersensitivity pneumonitis} OR sarcoidosis OR {obliterative 
bronchiolitis} OR {bronchiolitis obliterans} OR {cryptogenic obliterative bronchiolitis} OR 
{acute bronchiolitis} OR {diffuse pan-bronchiolitis} OR {follicular bronchiolitis} OR 
{aspiration bronchiolitis} OR {desquamative interstitial pneumonia}) AND (treatment OR 
therapy OR {drug therapy} OR thalidomide OR corticosteroids OR cyclophosphamide OR 
salbutamol OR {proton pump inhibitors} OR immunosuppressants OR pirfenidone OR 
nintendanib OR erythromycin OR macrolides OR {muscarinic antagonists} OR {beta 
agonist}) AND (adult OR adolescent)) AND ( LIMIT-TO(DOCTYPE,"ar" ) OR LIMIT-
TO(DOCTYPE,"re" ) OR LIMIT-TO(DOCTYPE,"cp" ) OR LIMIT-TO(DOCTYPE,"ip" ) ) AND ( 
LIMIT-TO(LANGUAGE,"English" ) ) 
 
Duplicates found between Scopus and PubMed searches were identified and 
removed in the EndNote library. 
 
 
 
CINAHL Searches  (EBSCOhost platform) – Cumulative Index of Nursing and Allied 
Health Literature - (1981 – present)  
Question 1: 
cough AND (“interstitial lung disease” OR “extrinsic allergic alveolitis” OR “anti-glomerular 
basement membrane disease” OR “Langerhans-cell histiocytosis” OR “idiopathic interstitial 
pneumonia” OR “organizing pneumonia” OR “cryptogenic fibrosing alveolitis” OR “non-
specific interstitial pneumonia” OR “radiation pneumonitis” OR “pulmonary sarcoidosis” OR 
“hypersensitivity pneumonitis” OR sarcoidosis OR “obliterative bronchiolitis” OR 
“bronchiolitis obliterans” OR “cryptogenic obliterative bronchiolitis” OR “acute bronchiolitis” 
OR “diffuse pan-bronchiolitis” OR “follicular bronchiolitis” OR “aspiration bronchiolitis” OR 
“desquamative interstitial pneumonia”) AND (etiology OR cause OR epidemiology OR 
prevalence OR diagnosis OR assessment OR investigation)  Limits:  All Adult and English 
Question 2: 
cough AND (“interstitial lung disease” OR “extrinsic allergic alveolitis” OR “anti-glomerular 
basement membrane disease” OR “Langerhans-cell histiocytosis” OR “idiopathic interstitial 
pneumonia” OR “organizing pneumonia” OR “cryptogenic fibrosing alveolitis” OR “non-
specific interstitial pneumonia” OR “radiation pneumonitis” OR “pulmonary sarcoidosis” OR 
“hypersensitivity pneumonitis” OR sarcoidosis OR “obliterative bronchiolitis” OR 
“bronchiolitis obliterans” OR “cryptogenic obliterative bronchiolitis” OR “acute bronchiolitis” 
OR “diffuse pan-bronchiolitis” OR “follicular bronchiolitis” OR “aspiration bronchiolitis” OR 
“desquamative interstitial pneumonia”) AND (treatment OR therapy OR drug therapy OR 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
thalidomide OR corticosteroids OR cyclophosphamide OR salbutamol OR proton pump 
inhibitors OR immunosuppressants OR pirfenidone OR nintendanib OR erythromycin OR 
macrolides OR “muscarinic antagonists” OR "beta agonist")  Limits:  All Adult and English 
Duplicates found between CINAHL and PubMed searches were identified and 
removed in the EndNote library.  
 
 
Cochrane Central Register of Controlled Trials (CENTRAL) (Wiley) 
Question 1: 
cough AND (“interstitial lung disease” OR “extrinsic allergic alveolitis” OR “anti-glomerular 
basement membrane disease” OR “Langerhans-cell histiocytosis” OR “idiopathic interstitial 
pneumonia” OR “organizing pneumonia” OR “cryptogenic fibrosing alveolitis” OR “non-
specific interstitial pneumonia” OR “radiation pneumonitis” OR “pulmonary sarcoidosis” OR 
“hypersensitivity pneumonitis” OR sarcoidosis OR “obliterative bronchiolitis” OR 
“bronchiolitis obliterans” OR “cryptogenic obliterative bronchiolitis” OR “acute bronchiolitis” 
OR “diffuse pan-bronchiolitis” OR “follicular bronchiolitis” OR “aspiration bronchiolitis” OR 
“desquamative interstitial pneumonia”) AND (etiology OR cause OR epidemiology OR 
prevalence OR diagnosis OR assessment OR investigation) 
Question 2: 
cough AND (“interstitial lung disease” OR “extrinsic allergic alveolitis” OR “anti-glomerular 
basement membrane disease” OR “Langerhans-cell histiocytosis” OR “idiopathic interstitial 
pneumonia” OR “organizing pneumonia” OR “cryptogenic fibrosing alveolitis” OR “non-
specific interstitial pneumonia” OR “radiation pneumonitis” OR “pulmonary sarcoidosis” OR 
“hypersensitivity pneumonitis” OR sarcoidosis OR “obliterative bronchiolitis” OR 
“bronchiolitis obliterans” OR “cryptogenic obliterative bronchiolitis” OR “acute bronchiolitis” 
OR “diffuse pan-bronchiolitis” OR “follicular bronchiolitis” OR “aspiration bronchiolitis” OR 
“desquamative interstitial pneumonia”) AND (treatment OR therapy OR drug therapy OR 
thalidomide OR corticosteroids OR cyclophosphamide OR salbutamol OR proton pump 
inhibitors OR immunosuppressants OR pirfenidone OR nintendanib OR erythromycin OR 
macrolides OR “muscarinic antagonists” OR "beta agonist")  
 
Duplicates found between CENTRAL and other database search results were 
identified and removed in the EndNote library 
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